- Home
- AMBC vs CELC Comparison
AMBC vs CELC Comparison
Compare AMBC & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBC
- CELC
- Stock Information
- Founded
- AMBC 1971
- CELC 2011
- Country
- AMBC United States
- CELC United States
- Employees
- AMBC N/A
- CELC N/A
- Industry
- AMBC Property-Casualty Insurers
- CELC Medical Specialities
- Sector
- AMBC Finance
- CELC Health Care
- Exchange
- AMBC Nasdaq
- CELC Nasdaq
- Market Cap
- AMBC 411.3M
- CELC 440.0M
- IPO Year
- AMBC 1991
- CELC 2017
- Fundamental
- Price
- AMBC $7.19
- CELC $13.79
- Analyst Decision
- AMBC Strong Buy
- CELC Strong Buy
- Analyst Count
- AMBC 1
- CELC 6
- Target Price
- AMBC $15.00
- CELC $30.67
- AVG Volume (30 Days)
- AMBC 940.8K
- CELC 204.8K
- Earning Date
- AMBC 08-04-2025
- CELC 08-13-2025
- Dividend Yield
- AMBC N/A
- CELC N/A
- EPS Growth
- AMBC N/A
- CELC N/A
- EPS
- AMBC N/A
- CELC N/A
- Revenue
- AMBC $253,912,000.00
- CELC N/A
- Revenue This Year
- AMBC N/A
- CELC N/A
- Revenue Next Year
- AMBC $17.41
- CELC N/A
- P/E Ratio
- AMBC N/A
- CELC N/A
- Revenue Growth
- AMBC 125.08
- CELC N/A
- 52 Week Low
- AMBC $5.99
- CELC $7.58
- 52 Week High
- AMBC $13.64
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- AMBC 49.52
- CELC 65.10
- Support Level
- AMBC $6.97
- CELC $12.48
- Resistance Level
- AMBC $7.22
- CELC $13.60
- Average True Range (ATR)
- AMBC 0.27
- CELC 0.77
- MACD
- AMBC 0.06
- CELC 0.10
- Stochastic Oscillator
- AMBC 90.79
- CELC 93.32
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. It operates in two principal businesses segments: Insurance Distribution and Specialty Property & Casualty Insurance. Insurance Distribution segment includes Managing General Agents, Underwriters and other appointed and delegated underwriting businesses (collectively MGAs or MGA/Us), an insurance broker, and other distribution and underwriting businesses. Specialty Property & Casualty Insurance includes five carriers (collectively, Everspan). Key revenue is generated from Insurance Distribution.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.